New Content  edit
Get The App!

Loading the player...
Monitoring of NOACs with TEG6S
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Ramin Artang, MD, discusses a University of Nebraska Medical Center study aimed at improving monitoring of NOACs. NOACs were initially thought to not require monitoring, however the practice of anticoagulating a patient requires some level of monitoring to ensure therapy is not only safe but is also effective. Evaluating outcomes alone in an anticoagulated patient is insufficient, particularly when the patient is having or could have an adverse event. There are many commercial approaches to monitoring NOACs, with the newest technology being TEG6S. The advantage of TEG6S is primarily that it is a point-of-care assay. With this assay, a clinician can know within 10 minutes whether a patient is in the sub- or supra- therapeutic range with a NOAC drug.